AMAG Pharmaceuticals (AMAG) Rocketing Higher After Receiving Positive News From FDA
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Join SI Premium – FREE
On April 30, 2009, AMAG Pharmaceuticals (Nasdaq: AMAG) is rising approximately 16% trading over $52 after receiving positive feedback from the FDA.
On April 30, 2009, AMAG Pharmaceuticals announced that the FDA informed AMAG Pharmaceuticals that the observations noted during the recent inspection of its’ Cambridge, Massachusetts manufacturing facility have been adequately addressed, and that a re-inspection of its manufacturing facility will not be required as a condition to approval of Feraheme™ (ferumoxytol injection).
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its technology for the development and commercialization of a therapeutic iron compound to treat anemia, and imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
On April 30, 2009, AMAG Pharmaceuticals announced that the FDA informed AMAG Pharmaceuticals that the observations noted during the recent inspection of its’ Cambridge, Massachusetts manufacturing facility have been adequately addressed, and that a re-inspection of its manufacturing facility will not be required as a condition to approval of Feraheme™ (ferumoxytol injection).
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its technology for the development and commercialization of a therapeutic iron compound to treat anemia, and imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
You May Also Be Interested In
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
